Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies.
Idoia GenuaKenneth CusiPublished in: Diabetes spectrum : a publication of the American Diabetes Association (2024)
Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.
Keyphrases
- type diabetes
- cardiovascular disease
- insulin resistance
- glycemic control
- metabolic syndrome
- weight loss
- healthcare
- primary care
- weight gain
- high fat diet induced
- physical activity
- early onset
- adipose tissue
- randomized controlled trial
- mass spectrometry
- body mass index
- coronary artery disease
- cardiovascular risk factors
- current status
- drug induced
- replacement therapy